Unlearn
About Unlearn
Unlearn is a healthcare AI company that is revolutionizing clinical trials through the creation and application of “digital twins” of patients. For physicians, this means a significant advancement in how new treatments are developed and evaluated. Unlearn’s proprietary technology, including its DiGenesis™ process and TwinRCTs™, utilizes generative AI models to create simulated clinical records that predict individual health outcomes under various treatment scenarios. This allows for the development of intelligent control arms in clinical studies, reducing the need for large placebo groups and enabling more patients to receive potentially beneficial experimental treatments.
The core benefit for the medical community is the acceleration and ethical improvement of clinical research. By leveraging digital twins, Unlearn aims to make clinical trials faster, smaller, and more efficient, ultimately bringing life-saving therapies to patients sooner. The company’s methods have received qualification from the European Medicines Agency (EMA) and align with FDA guidance, indicating a robust and credible scientific approach. This technology can also assist healthcare professionals in personalizing treatment plans, monitoring patient progress, and making more informed decisions by simulating the effects of different treatments on an individual patient’s biology.
Focus Areas
Business Intelligence
| Key Investors | Altimeter Capital, Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, Necessary Venture Capital, Insight Partners, 8VC, DCVC, DCVC Bio |
| Partnerships | VectorY Therapeutics, remynd, Trace Neuroscience, ProJenX, SOLA Biosciences, Merck KGaA |
| Technology | AI-powered digital twin technology, generative machine learning models, proprietary DiGenesis™ process, PROCOVA™ (Prognostic Covariate Adjustment) statistical approach, TrialPioneer (unified workspace for trial planning) |
What the Web Says
Unlearn.AI is a company that utilizes AI-generated 'digital twins' to accelerate clinical trials by reducing the need for large placebo groups and shortening trial durations. The company generally receives positive feedback for its innovative approach to clinical research and its potential to reduce costs and time in drug development. Employee reviews, though limited, suggest a positive work culture and leadership, although some areas for improvement were noted.
Overall: PositiveStrengths
- Uses advanced AI models and digital twins to simulate individual health outcomes, personalizing clinical trials.
- Accelerates clinical drug development and enables faster clinical trial enrollment by requiring fewer patients.
- Reduces clinical trial costs by 30-50% through virtual patient cohort simulation.
- Strengthens trial analyses by reducing variability and improving the ability to detect treatment effects.
- Positive work culture, leadership, and high employee satisfaction in areas like retention.
- Offers customized development tracks for employees.
Limitations
- Implementation of Unlearn.AI's technology could be costly.
- Potential for job loss in the clinical trial sector due to automation.
- AI lacks the ability to understand emotion and replicate human creativity, potentially limiting its application in some clinical trial areas.
- Accuracy of predictions can be impacted by the quality and integrity of the data used to create digital twins.
- Requires extensive clinical data for initial model calibration and ongoing validation.
- Adoption requires significant cultural change in organizations accustomed to traditional trial designs.
Based on reviews from: Comparably, Unlearn.ai Customer Reviews, Biology Digital, Unlearn.AI Official Website, Dennis Gong Blog, Forbes, Built In San Francisco, Life Sciences Today Podcast, Reddit
Last updated: 2026-06-23
Videos
News, demos, and interviews about Unlearn.
Videos load interactively. If none appear, search YouTube for Unlearn →
Press & Coverage
Frequently Asked Questions
Investors
Who's funded Unlearn.
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]